ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C16H15N3O3
CAS番号:
分子量:
297.31
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥97% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥97% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white to off-white
solubility
DMSO: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
SMILES string
N(c3ccc(cc3)O)c1ncnc2c1cc(c(c2)OC)OC
InChI
1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-3-5-11(20)6-4-10/h3-9,20H,1-2H3,(H,17,18,19)
InChI key
HOZUXBLMYUPGPZ-UHFFFAOYSA-N
General description
A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 µM). Has no effect on JAK1, JAK2, or Zap/Syk or Src tyrosine kinases. Acts as a potent inhibitor of glioblastoma cell adhesion and migration. Also reported to block thrombin-induced platelet aggregation.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Janus family kinase 3
Janus family kinase 3
Product competes with ATP.
Reversible: yes
Target IC50: 78 µM against Janus family kinase 3
Packaging
Packaged under inert gas
Other Notes
Tibbles, H.E., et al. 2001. J. Biol. Chem.276, 17815.
Sudbeck, E.A., et al. 1999. Clin. Cancer Res.5, 1569.
Goodman, P.A., et al. 1998. J. Biol. Chem. 273, 17742.
Narla, R.K., et al. 1998. Clin. Cancer Res. 4, 2463.
Sudbeck, E.A., et al. 1999. Clin. Cancer Res.5, 1569.
Goodman, P.A., et al. 1998. J. Biol. Chem. 273, 17742.
Narla, R.K., et al. 1998. Clin. Cancer Res. 4, 2463.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
一体何が起きているの?
WGK 1
引火点 (F)
Not applicable
引火点(°C)
Not applicable